Halsey ES et al.2013. Mayaro virus infection, Amazon Basin region, Peru, 2010–2013. Emerg Infect Dis 19: 1839–1842.
Bouquillard E , Combe B , 2009. Rheumatoid arthritis after Chikungunya fever: a prospective follow-up study of 21 cases. Ann Rheum Dis 68: 1505–1506.
Anderson CR , Downs WG , Wattley GH , Ahin NW , Reese AA , 1957. Mayaro virus: a new human disease agent: II. Isolation from blood of patients in Trinidad, B.W.I. Am J Trop Med Hyg 6: 1012–1016.
Pinheiro FP , Freitas RB , Travassos da Rosa JF , Gabbay YB , Mello WA , LeDuc JW , 1981. An outbreak of Mayaro virus disease in Belterra, Brazil: I. Clinical and virological findings. Am J Trop Med Hyg 30: 674–681.
Talarmin A et al.1998. Mayaro virus fever in French Guiana: isolation, identification, and seroprevalence. Am J Trop Med Hyg 59: 452–456.
Tesh RB et al.1999. Mayaro virus disease: an emerging mosquito-borne zoonosis in tropical South America. Clin Infect Dis 28: 67–73.
Torres JR et al.2004. Family cluster of Mayaro fever, Venezuela. Emerg Infect Dis 10: 1304–1306.
Powers AM et al.2006. Genetic relationships among Mayaro and Una viruses suggest distinct patterns of transmission. Am J Trop Med Hyg 75: 461–469.
Azevedo RS et al.2009. Mayaro fever virus, Brazilian Amazon. Emerg Infect Dis 15: 1830–1832.
Mourão MP et al.2012. Mayaro fever in the city of Manaus, Brazil, 2007–2008. Vector Borne Zoonotic Dis 12: 42–46.
Terzian AC et al.2015. Isolation and characterization of Mayaro virus from a human in Acre, Brazil. Am J Trop Med Hyg 92: 401–404.
Llagonne-Barets M et al.2016. A case of Mayaro virus infection imported from French Guiana. J Clin Virol 77: 66–68.
Lednicky J et al.2016. Mayaro virus in child with acute febrile illness, Haiti, 2015. Emerg Infect Dis 22: 2000–2002.
Auguste AJ et al.2015. Evolutionary and ecological characterization of Mayaro virus strains isolated during an outbreak, Venezuela, 2010. Emerg Infect Dis 21: 1742–1750.
de Omota M , Avilla C , Nogueira M , 2019. Mayaro virus: a neglected threat could cause the next worldwide viral epidemic. Future Virol 14: 375–377.
LeDuc JW , Pinheiro FP , Travassos da Rosa AP , 1981. An outbreak of Mayaro virus disease in Belterra, Brazil: II. Epidemiology. Am J Trop Med Hyg 30: 682–688.
Yactayo S , Staples JE , Millot V , Cibrelus L , Ramon-Pardo P , 2016. Epidemiology of Chikungunya in the Americas. J Infect Dis 214: S441–S445.
Halstead SB , 2015. Reappearance of Chikungunya, formerly called Dengue, in the Americas. Emerg Infect Dis 21: 557–561.
Martins KA et al.2019. Neutralizing antibodies from convalescent Chikungunya virus patients can cross-neutralize Mayaro and Una viruses. Am J Trop Med Hyg 100: 1541–1544.
Webb EM et al.2019. Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potential. Sci Rep 9: 20399.
Santiago FW et al.2015. Long-term arthralgia after Mayaro virus infection correlates with sustained pro-inflammatory cytokine response. PLoS Negl Trop Dis 9: e0004104.
Juarez D , Long KC , Aguilar P , Kochel TJ , Halsey ES , 2013. Assessment of plaque assay methods for alphaviruses. J Virol Methods 187: 185–189.
Forshey BM et al.2010. Arboviral etiologies of acute febrile illnesses in western South America, 2000–2007. PLoS Negl Trop Dis 4: e787.
Watts DM et al.1997. Venezuelan equine encephalitis and Oropouche virus infections among Peruvian army troops in the Amazon region of Peru. Am J Trop Med Hyg 56: 661–667.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||92||55||8|
Mayaro virus (MAYV) is an alphavirus endemic to both Latin America and the Caribbean. Recent reports have questioned the ability of MAYV and its close relative, Chikungunya virus (CHIKV), to generate cross-reactive, neutralizing antibodies to one another. Since CHIKV was introduced to South America in 2013, discerning whether individuals have cross-reactive antibodies or whether they have had exposures to both viruses previously has been difficult. Using samples obtained from people infected with MAYV prior to the introduction of CHIKV in the Americas, we performed neutralizing assays and observed no discernable neutralization of CHIKV by sera from patients previously infected with MAYV. These data suggest that a positive CHIKV neutralization test cannot be attributed to prior exposure to MAYV and that previous exposure to MAYV may not be protective against a subsequent CHIKV infection.
Financial support: This study was supported in part by the National Institutes of Health (grant no. R24 AI120942) and by the U.S. Department of Defense Health Agency, Armed Forces Health Surveillance Division, Global Emerging Infections Surveillance Branch: Work Unit No. 800000.82000.25GB.B0016. ProMIS ID: P0144_20_N6 2011–2012.
Disclosure: C. S., C. G., S. V., E. S. H., and J. S. A. are employees of the U.S. government. This work was prepared as part of their official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not available for any work of the U.S. government. Title 17, U.S.C., §101 defines a U.S. government work as a work prepared by an employee of the U.S. government as part of that person’s official duties. The study protocol was approved by the U.S. Naval Medical Research Unit No. 6 Institutional Review Board (protocol NMRCD.2010.0010) in compliance with all applicable federal regulations governing the protection of human subjects.
Disclaimer: The views expressed in this article reflect the results of research conducted by the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. government.
Authors’ addresses: Nathen E. Bopp, Department of Pathology, University of Texas Medical Branch, Galveston, TX, E-mail: email@example.com. Kara J. Jencks, School of Medicine, University of Texas Medical Branch, Galveston, TX, E-mail: firstname.lastname@example.org. Crystyan Siles, Carolina Guevara, Stalin Vilcarromero, Eric S. Halsey, and Julia S. Ampuero, U.S. Naval Medical Research Unit No. 6, Lima, Peru, E-mails: email@example.com, firstname.lastname@example.org, email@example.com, firstname.lastname@example.org, and email@example.com. Diana Fernández, Department of Pathology, University of Texas Medical Branch, Galveston, TX, and Center for Tropical Diseases, University of Texas Medical Branch, Galveston, TX, E-mail: firstname.lastname@example.org. Patricia V. Aguilar, Department of Pathology, University of Texas Medical Branch, Galveston, TX, Center for Tropical Diseases, University of Texas Medical Branch, Galveston, TX, and Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, E-mail: email@example.com.